Literature DB >> 19524170

Serious infections due to methicillin-resistant Staphylococcus aureus: an evolving challenge for physicians.

Marco Falcone1, Pietro Serra, Mario Venditti.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is a well-recognized major cause of nosocomial infection worldwide. During the past decade, however, the epidemiology of staphylococcal infections has partially changed, with an increase in the number of patients who acquire infections in the community. The changing epidemiology is a cause for concern among physicians, leading to an increase in the number of patients with infections due to MRSA diagnosed at hospital admission and in the emergency department. The aims of this article are to review the current state of knowledge regarding MRSA infections, to identify those factors which may help physicians to recognize the patients at high risk, and to manage these infections appropriately.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19524170     DOI: 10.1016/j.ejim.2008.08.016

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  9 in total

1.  Identifying patients with acute bacterial skin and skin structure infection who need blood cultures.

Authors:  Giusy Tiseo; Antonino Mazzone; Marco Falcone
Journal:  Intern Emerg Med       Date:  2019-01-01       Impact factor: 3.397

Review 2.  Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs.

Authors:  Marco Falcone; Ercole Concia; Massimo Giusti; Antonino Mazzone; Claudio Santini; Stefania Stefani; Francesco Violi
Journal:  Intern Emerg Med       Date:  2016-04-15       Impact factor: 3.397

3.  In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.

Authors:  Kimberly D Leuthner; Celine Vidaillac; Chrissy M Cheung; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

4.  Clinical impact of broad-spectrum empirical antibiotic therapy in patients with healthcare-associated pneumonia: a multicenter interventional study.

Authors:  Marco Falcone; Salvatore Corrao; Giuseppe Licata; Pietro Serra; Mario Venditti
Journal:  Intern Emerg Med       Date:  2012-06-12       Impact factor: 3.397

Review 5.  Pneumonia in frail older patients: an up to date.

Authors:  Marco Falcone; Francesco Blasi; Francesco Menichetti; Federico Pea; Francesco Violi
Journal:  Intern Emerg Med       Date:  2012-06-12       Impact factor: 3.397

6.  Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin.

Authors:  M E Pachón-Ibáñez; S Ribes; M A Domínguez; R Fernández; F Tubau; J Ariza; F Gudiol; C Cabellos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-16       Impact factor: 3.267

7.  Inactivation of the Ecs ABC transporter of Staphylococcus aureus attenuates virulence by altering composition and function of bacterial wall.

Authors:  Ing-Marie Jonsson; Jarmo T Juuti; Patrice François; Rana AlMajidi; Milla Pietiäinen; Myriam Girard; Catharina Lindholm; Manfred J Saller; Arnold J M Driessen; Pentti Kuusela; Maria Bokarewa; Jacques Schrenzel; Vesa P Kontinen
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

8.  Cationic antimicrobial peptides: alternatives and/or adjuvants to antibiotics active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa.

Authors:  Regina Geitani; Carole Ayoub Moubareck; Lhousseine Touqui; Dolla Karam Sarkis
Journal:  BMC Microbiol       Date:  2019-03-08       Impact factor: 3.605

9.  Brazilian experience in EU-CORE: daptomycin registry and treatment of serious Gram-positive infections.

Authors:  Artur Timerman; Carlos Brites; Eliana Bicudo; Renato S Grinbaum; Rubens Costa Filho; Claudia D M Carrilho; Andre Bichels; Tânia Barreto
Journal:  Braz J Infect Dis       Date:  2013-07-31       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.